Latest news with #GraftVersusHostDisease
Yahoo
19-05-2025
- Business
- Yahoo
Graft Versus Host Disease (GVHD) Global Clinical Trials Review 2025: Unlocking Strategies from GVHD Clinical Trials Across G7 & E7 Regions
Dublin, May 19, 2025 (GLOBE NEWSWIRE) -- The "Graft Versus Host Disease (GVHD) - Global Clinical Trials Review, 2025" has been added to offering. The report offers a comprehensive analysis of the GVHD clinical trial landscape worldwide. Presenting top-line data, this report furnishes details about the number of trials and their average enrollment across major countries. It covers trials by region, country (G7 & E7), phase, status, endpoints, and sponsor types. This report also highlights key drugs involved in ongoing trials, curated from the Pharma Clinical Trials Database. This database consolidates information from over 80 global trial registries, conferences, journals, and news sources and is periodically updated through a dynamic process to ensure data accuracy and relevance. The insights provided in this report enhance strategic decision-making and help formulate effective strategies to gain a competitive edge. Scope Provides a snapshot of the global clinical trials landscape, offering top-level data by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type, and End Point Status. Reviews leading companies in the sector and lists all relevant trials with titles, phases, and statuses. Details unaccomplished trials, including terminated, suspended, and withdrawn, along with reasons for uncompletion. Shows enrollment trends over the past five years and shares the latest news from the past three months. Specific sections might be modified based on data availability and relevance to the disease. Reasons to Buy Supports strategic business investment decisions. Identifies optimal locations for cost-effective and timely clinical trials. Provides a top-level analysis of the Global Clinical Trials Market, pinpointing key business opportunities. Clarifies trial count and enrollment trends globally, aiding market understanding. Compares completed with incomplete trials to assist in interpreting clinical trial success rates. Offers an assessment of trials at global, regional, and country levels. Sections may be customized based on data relevancy to the implicated disease. Key Topics Covered: Report Guidance Clinical Trials by Region Clinical Trials and Average Enrollment by Country Top Five Countries Contributing to Clinical Trials in Asia-Pacific Top Five Countries Contributing to Clinical Trials in Europe Top Countries Contributing to Clinical Trials in North America Top Five Countries Contributing to Clinical Trials in Middle East and Africa Top Five Countries Contributing to Clinical Trials in Central and South America Clinical Trials by G7 Countries Clinical Trials by Phase Clinical Trials by Trial Status Clinical Trials by End Point Status Subjects Recruited Over a Period of Time Clinical Trials by Sponsor Type Prominent Sponsors Top Companies Participating in Graft Versus Host Disease (GVHD) Therapeutics Clinical Trials Prominent Drugs Latest Clinical Trials News on Graft Versus Host Disease (GVHD) Clinical Trial Profile Snapshots Appendix A selection of companies mentioned in this report includes, but is not limited to: Sanofi Incyte Corp Novartis AG Johnson & Johnson Pfizer Inc Takeda Pharmaceutical Co Ltd Mallinckrodt Plc Roche Holding AG Bristol-Myers Squibb Co Bellicum Pharmaceuticals Inc For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
Globe and Mail
13-03-2025
- Business
- Globe and Mail
Graft Versus Host Disease Market is Projected for Substantial Expansion from USD 1.3 Billion in 2023
The key Graft Versus Host Disease companies including CSL Behring, Equillium, Biocon, MaaT Pharma, REGiMMUNE, ReAlta Life Sciences, Ono Pharmaceutical (Deciphera Pharmaceuticals), Medsenic, BioSenic, ASC Therapeutics, Cynata Therapeutics, Evive Biotech (Yifan Pharmaceutical), Ironwood, Medac, and others The 7MM Graft Versus Host Disease (GvHD) market has demonstrated substantial growth in recent years, fueled by rising transplant rates, an aging population, and the introduction of innovative therapies such as ZEMAIRA, EQ001, MaaT013, and RGI-2001, among others. According to DelveInsight's comprehensive analysis, key pharmaceutical companies including ICSL Behring, Equillium, Biocon, MaaT Pharma, REGiMMUNE, ReAlta Life Sciences, Ono Pharmaceutical (Deciphera Pharmaceuticals), Medsenic, BioSenic, ASC Therapeutics, Cynata Therapeutics, Evive Biotech (Yifan Pharmaceutical), Ironwood, Medac, and others leading innovation in this space. DelveInsight's ' Graft Versus Host Disease Market Insights, Epidemiology, and Market Forecast – 2034 ' report provides an in-depth understanding of Graft Versus Host Disease (GvHD), historical and forecasted epidemiology, as well as the Graft Versus Host Disease market trends in the 7MM which include the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. The GvHD market forecast anticipates a CAGR of 8.2% through 2034 over the study period (2020-2034) from USD 1.3 Billion in 2023. Regionally, the United States represents around 70% of the GvHD market, thanks to favorable reimbursement policies and rapid adoption of new, premium-priced therapies. The EU4 and the UK together account for about 19% of the GvHD market. Download the GvHD market report to understand which factors are driving the Graft Versus Host Disease therapeutic market @ Graft Versus Host Disease Market Trends The report also analyzes historical and projected epidemiology segmented by total allogenic transplant cases, total Graft Versus Host Disease prevalence, type-specific cases of Graft Versus Host Disease, Graft Versus Host Disease cases by grading, Graft Versus Host Disease cases by organ involvement, Graft Versus Host Disease cases by grading, Graft Versus Host Disease cases by organ involvement, total treated cases of Graft Versus Host Disease, and mortality adjusted treated cases of Graft Versus Host Disease. DelveInsight estimates approximately 52K cases of Graft Versus Host Disease in the 7MM. In 2023, the EU4 and the UK recorded the highest incidence of Grade D[IV] Graft-Versus-Host Disease, aligning with patterns observed in hematologic malignancy transplants. Discover evolving trends in Graft Versus Host Disease patient pool forecasts @ Graft Versus Host Disease Epidemiology Analysis. The Graft Versus Host Disease Treatment Market Report provides insights into current GvHD treatment practices, emerging drugs, market share of individual therapies, and forecasts for the 7MM GvHD market size from 2020 to 2034. Current Graft Versus Host Disease therapies include steroids, NIKTIMVO, JAKAFI, IMBRUVICA, RYONCIL/TEMCELL HS, and ORENCIA, among others. Graft Versus Host Disease Treatment is evolving from broad immunosuppression to targeted and cell-based therapies. JAKAFI (ruxolitinib), a JAK1/JAK2 inhibitor, is a cornerstone of GvHD treatment and generates substantial revenue due to its proven efficacy in steroid-refractory cases. DelveInsight's analysis indicates that the GvHD clinical trials market is highly active, with numerous investigational therapies in various stages of development. Notable candidates include ZEMAIRA (CSL Behring), EQ001 (Equillium/Biocon), MaaT013 (MaaT Pharma), RGI-2001 (REGiMMUNE), MC0518 (Medac), RLS-0071 (ReAlta Life Sciences), VIMSELTINIB (Deciphera Pharmaceuticals), ARSCIMED (Medsenic/BioSenic), ASC-930 (ASC Therapeutics), CYP-001 (Cynata Therapeutics), F-652 (Yifan Pharmaceutical), and APRAGLUTIDE (Ironwood), among others. Unlock which Graft Versus Host emerging Disease drug is expected to capture the largest market share in 7MM by 2034. Visit the Graft Versus Host Disease Market Insights. In January 2025, the FDA approved Incyte's and Syndax's Niktimvo (axatilimab-csfr) in 9 mg and 22 mg vial sizes for the treatment of chronic graft-versus-host disease (GVHD) in adults and pediatric patients based on data from the AGAVE-201 trial. This demonstrates encouraging progress in the graft versus host disease clinical trials market. Upcoming milestones may include potential label expansions of cellular therapies like mesenchymal stromal cells, which could redefine first-line treatment strategies. However, challenges remain, such as standardizing response criteria across clinical trials and addressing the financial strain associated with chronic graft versus host disease treatment. DelveInsight's report emphasizes that overcoming these challenges will require collaboration among pharmaceutical stakeholders and transplant networks to optimize patient stratification and track outcomes effectively. Table of Contents 1. Key Insights 2. Report Introduction 3. GvHD Market Overview at a Glance 4. Executive Summary 5. Key Events 6. Disease Background and Overview 7. Methodology 8. Epidemiology and Patient Population 9. Patient Journey 10. Marketed Drugs 11. Emerging Drugs 12. GvHD – 7MM Market Analysis 13. KOL Views 14. Unmet Needs 15. SWOT Analysis 16. Market Access and Reimbursement 16.1. The US 17. Appendix 18. DelveInsight Capabilities 19. Disclaimer 20. About DelveInsight Related Reports Graft versus host disease (GvHD) Pipeline Insight Graft versus host disease Pipeline Insight provides comprehensive insights about the GvHD pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the GvHD companies, including Abbisko Therapeutics, Equillium, Theriva Biologics, Seres Therapeutics, CytoMed Therapeutics, Beijing Tide Pharmaceutical Co., Ltd, CTI BioPharma, ViGenCell Inc., Lipella Pharmaceuticals, Cellestia Biotech, Seres Therapeutics, Jiangsu HengRui Medicine Therapeutics, Genentech, AltruBio, Orca Bio, GSK and Amgen among others. About DelveInsight DelveInsight is a leading market research and consulting firm specializing in disease-specific insights and therapeutic market analysis. Their reports integrate real-world data, clinical trial findings, and expert interviews to deliver comprehensive industry intelligence. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Arpit Anand Email: Send Email Phone: +14699457679 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: Nevada Country: United States Website:
